The 2nd SAPA-GP Annual Conference Program
Current Trends in
World Pharmaceutical and Biotech R&D
Saturday,
June 5, 2004
Gwynedd-Mercy
College, Pennsylvania
8:45 am
– 8:50 am Welcome Remarks
8.50 am
– 9:30 am Dr. Susan Dillon
Senior
Vice President, Discovery Research, Centocor, Johnson & Johnson
9:30 am
– 10:10 am Dr. Zhenping Zhu
Assistant Vice President & Head, Antibody Technology, ImClone Systems
Inc.
The
Story of Erbitux – Development of the Anti-EGFR Monoclonal Antibody for Treating
Metastatic Colon Cancer
10:10 am – 10:30 am Coffee Break
10:30 am
– 11:10 am Dr. Kei-Lai Fong
Consultant & Vice President, Bioanalytical/DMPK, Calvert Laboratories
Optimizing
Drug Development: Strategies to Accelerate Early Development
11:10 am – 11:50 am Dr. John Lewis
Senior Director, Merck Research
Laboratories
Scrapied
Sheep to Mad Cows: Recent Adventures of the BSE Rogue Protein
11:50am –12:10 am
SAPA-GP Corporate Excellence Award
Presentation& SAPA-GP Election Results Announcement
Luncheon
12:10 pm to 1:30 pm
Afternoon
Session
Integrated
Clinical Development - From Preclinical through to File
2:10 pm –
2:50 pm Dr. J. Joseph Kim
Co-Founder,
President & CEO, VGX Pharmaceuticals
2:50 pm – 3:10 pm Coffee Break
3:10 pm – 3:35 pm Dr. James Li
Hypertension
Franchise, Asia, Merck & Co.
3:35 pm – 4:00 pm Mr.
Mark Gao
Managing Director & CEO,
MCHEM Pharma Group, Xiamen, China
4:00 pm – 4:25 pm Dr. Zi-Qiang Gu
FDA
Co-Founder & Vice President,
Synergetica Inc.
How Do We Change the Business
Idea into the Business Reality
Vice-President, Qilu Pharmaceuticals, and Director,
Drug R&D Division.
Current Status of Drug R&D in China
Dinner
– 6:30 pm to 8:30 pm